BCRX BioCryst Pharmaceuticals Inc
Company Analysis
Latest News
🔴 BioCryst Pharmaceuticals is trading 9.0% down in pre-market — no clear catalyst identified
BioCryst Pharmaceuticals is trading 9.0% down at $7.30 in pre-market, with no specific catalyst identified. - No clear company-specific announcement...
🟢 BioCryst Pharmaceuticals is trading 8.07% up in pre-market with no clear catalyst identified
BioCryst Pharmaceuticals is trading 8.07% higher in pre-market at $8.70, with no specific catalyst identified for the move. - The price is compared with the...
🟢 BioCryst Pharmaceuticals is trading 4.58% up in after-hours trading — with no clear catalyst identified
BioCryst Pharmaceuticals is trading at $8.44, up 4.58% in after-hours trading, with no clear company-specific catalyst identified. - No confirmed BioCryst...
🔴 BioCryst Pharmaceuticals is trading 10.74% down in pre-market — reason remains unclear
BioCryst Pharmaceuticals is trading at $7.40, down 10.74% in pre-market, with the reason for the decline unclear. - No clear company-specific announcement...
🟢 BioCryst Pharmaceuticals is trading 4.28% up on October 7, 2026 — no clear catalyst identified
BioCryst Pharmaceuticals is trading at $8.29, up 4.28%, with the reason for the October 7 gain unclear. - The seven-member scientific advisory board was...
🟢 BioCryst Pharmaceuticals is trading 9.4% up in pre-market; no confirmed catalyst
BioCryst Pharmaceuticals is trading at $8.70, up 9.43% in pre-market, with no confirmed company-specific catalyst for the October 7 move. - The price is...
🟢 BioCryst Pharmaceuticals is trading 4.8% up in pre-market with catalyst attribution unconfirmed
BioCryst Pharmaceuticals is trading 4.8% higher in pre-market at $8.49 on October 6, versus the October 5 close of $8.10; available sources do not confirm a...
🔴 BioCryst Pharmaceuticals is trading 6.5% down today after Pharvaris’s positive late-stage hereditary-angioedema results
BioCryst Pharmaceuticals is trading 6.5% down at $8.23 after continued pressure from Pharvaris’s positive late-stage hereditary-angioedema trial results, which...
🔴 BioCryst Pharmaceuticals is trading 7.63% down today
BioCryst Pharmaceuticals is trading at $9.20, -7.63%, with no clear company-specific catalyst identified for September 8, 2026. - The latest announcement was...
🔴 BioCryst Pharmaceuticals is trading 4.2% down in pre-market with no clear company-specific catalyst identified
BioCryst Pharmaceuticals is trading 4.2% down now at $9.54 after no clear company-specific catalyst was identified for September 8, 2026. - The latest company...
🔴 BioCryst Pharmaceuticals is trading 4.26% down in pre-market
BioCryst Pharmaceuticals is trading 4.26% down at $9.41 after no clear negative company-specific catalyst was identified for August 26, 2026. - The latest...
🔴 BioCryst Pharmaceuticals is trading 4.37% down today amid broader biotech profit-taking
BioCryst Pharmaceuticals is trading at $9.63, with a -4.37% move on August 20, 2026, amid biotech profit-taking after the previous session’s Moderna-driven...
🟢 BioCryst Pharmaceuticals rises 4.1% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🟢 BioCryst Pharmaceuticals is trading 5.6% up today in pre-market following stronger-than-expected Q2 results
BioCryst Pharmaceuticals is trading 5.63% up now at $10.50, with continued buying potentially supported by its August 5 earnings report. - The report showed...
🔴 BioCryst Pharmaceuticals is trading 4.15% down today with no clear catalyst identified
BioCryst Pharmaceuticals is trading 4.15% down at $10.15, with no clear company-specific announcement or analyst action identified for August 13, 2026. - The...
🟢 BioCryst Pharmaceuticals is trading 5% up today after guidance rose to $690 million–$715 million
BioCryst Pharmaceuticals is trading $10.32 (+4.88%) after management raised 2026 total revenue guidance. • The move extends the 4.90% gain recorded on August...
🟢 BioCryst Pharmaceuticals is trading 4.05% up today after second-quarter revenue beat and higher 2026 guidance
BioCryst Pharmaceuticals is trading at $9.76, up +4.05%, extending gains after its August 5 second-quarter results. - Revenue reached $218.3 million, beating...
BioCryst's Blowout Quarter Looks Great on Paper — But Can a One-Time Licensing Windfall Justify a Lasting Rally?
Shares jumped 8.6% in pre-market as BioCryst Pharmaceuticals delivered a quarter that topped Wall Street on every line. Revenue of $218.3 million surged 34%...
🟢 BioCryst Pharmaceuticals is trading 4.02% up today after Q2 revenue and EPS beat expectations
BioCryst Pharmaceuticals is trading 4.02% up at $9.44 after its August 5, 2026, second-quarter results beat expectations. - Revenue reached $218.3 million,...
🟢 BioCryst Pharmaceuticals is trading 6.8% up today after beating Q2 estimates and raising its FY26 revenue outlook
BioCryst Pharmaceuticals is trading 6.8% up at $9.63 after reporting better-than-expected second-quarter 2026 results and raising its full-year revenue...